USPTO Examiner LIPPERT JOHN WILLIAM - Art Unit 1615

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18977838LEONURINE NANOCOMPOSITE HYDROGEL AND PREPARATION METHODS AND APPLICATIONS THEREOFDecember 2024April 2025Allow410NoNo
18761898MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESJuly 2024January 2025Allow710YesNo
18762128MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMESJuly 2024February 2025Allow710YesNo
18565894CATIONIC LIPID COMPOUND, COMPOSITION CONTAINING SAME AND USE THEREOFNovember 2023September 2024Allow1010NoNo
18038871PEPTIDE HAVING PROTECTIVE ACTIVITY AGAINST CELL DAMAGE CAUSED BY PARTICULATE MATTER, AND USES FOR SAMEMay 2023July 2025Allow2500YesNo
18321613PREPARATION METHOD AND APPLICATION OF TUMOR MICROPARTICLES ENCAPSULATING METABOLIC INHIBITORSMay 2023June 2025Allow2500YesNo
18156534SKIN WHITENING COMPOSITIONJanuary 2023April 2024Abandon1510NoNo
18081752COSMETIC COMPOSITION COMPRISING POLYACRYLATE CROSSPOLYMER-6, AND SILICA AND/OR LAUROYL LYSINEDecember 2022February 2025Abandon2630NoNo
17994217SUSTAINED-RELEASE PHEROMONE PREPARATIONNovember 2022June 2025Allow3030YesNo
17979303COSMETIC PRODUCT COMPRISING OIL DISCONTINUOUS PHASE AND METHOD OF USE THEREOFNovember 2022May 2024Abandon1810NoNo
17978667PRODUCTION PROCESS OF A CONVENIENT AND QUICK-ADHESIVE EYELASHESNovember 2022April 2024Abandon1710NoNo
17970649SKIN HEALTH PRESERVATION TREATMENT FORMULATIONOctober 2022October 2024Abandon2321NoNo
17957707ACIDIC BONDING COMPOSITIONS AND METHODS FOR RESTORING AND COLOR TONING LIGHTENED HAIRSeptember 2022January 2025Allow2731YesYes
17956528PHARMACEUTICAL FORMULATION CONTAINING A PSYCHEDELIC SUBSTANCE OBTAINED BY SELECTIVE LASER SINTERING (SLS) 3D PRINTINGSeptember 2022August 2024Abandon2310NoNo
17812746HEMOSTATIC NANOCAPSULES FOR STOPPING BLEEDING, VISUALIZING INJURY, AND DELIVERING DRUGSJuly 2022August 2024Allow2511NoNo
17843703FULLERENE GALLIUM PHOSPHONATE AND METHODSJune 2022June 2025Abandon3610NoNo
17774575NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOFMay 2022May 2025Allow3710YesNo
17737982LIGHT STABLE SILVER CONTAINING NEAR NEUTRAL pH DISINFECTANT AND METHOD OF PREPARATIONMay 2022August 2024Allow2710NoNo
17771856STABILIZED AMORPHOUS CALCIUM MAGNESIUM PHOSPHATE PARTICLE COMPOSITIONSApril 2022April 2025Allow3501NoNo
17768543PERSONAL CARE FORMULATIONApril 2022April 2025Allow3610NoNo
17765893THREE-DIMENSIONAL FLOW PATH STRUCTURE BODY AND NANOPARTICLE PRODUCTION METHOD USING SAMEApril 2022May 2025Abandon3710NoNo
17764432ANTI-UV COSMETIC COMPOSITIONMarch 2022May 2025Abandon3710NoNo
17640749EXTRACELLULAR VESICLE-FENRETINIDE COMPOSITIONS, EXTRACELLULAR VESICLE-C-KIT INHIBITOR COMPOSITIONS, METHODS OF MAKING AND USES THEREOFMarch 2022March 2025Abandon3710NoNo
17597232ISOXAZOLINE COMPOUNDS AND USE THEREOFDecember 2021April 2025Allow3910NoNo
17615967OIL-IN-WATER TYPE EMULSION LIP COSMETICDecember 2021June 2025Abandon4320NoNo
17595156LIPID NANOPARTICLENovember 2021May 2025Allow4320YesNo
17609958MICROPARTICLES COMPRISING CELLULOSE NANOCRYSTALS AGGREGATED WITH PROTEINS AND COSMETIC USES THEREOFNovember 2021December 2024Abandon3710NoNo
17437290EYE DROPS CONTAINING CHITOSAN NANOPARTICLES IN WHICH PDRN IS ENCAPSULATED, AND PREPARATION METHOD THEREFORNovember 2021May 2025Allow4520NoNo
17606718PRODUCTS OF MANUFACTURE AND METHODS FOR TRANSDERMAL DELIVERY OF PHARMACEUTICALS, ELECTROLYTES, AND NUTRICEUTICALSOctober 2021January 2025Abandon3810NoNo
17603339USE OF GOLD NANOCLUSTERS IN TREATING HYPERCHOLESTEROLEMIA OR HYPERCHOLESTEROLEMIA-ASSOCIATED DISEASESOctober 2021May 2025Abandon4320NoNo
17601144ANTISEPTIC SKIN PREP COMPOSITIONOctober 2021April 2025Allow4220NoNo
17600965SOLID NANOPARTICLE FORMULATION OF WATER INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD RIPENING AND IMMEDIATE DRUG RELEASE FOLLOWING INTRAVENOUS ADMINISTRATIONOctober 2021November 2024Abandon3810NoNo
17593981PERSONAL CARE COMPOSITIONS AND METHODS COMPRISING TRANS-1-CHLORO-3,3,3-TRIFLUOROPROPENE AND TRANS-1,3,3,3-TETRAFLUOROPROPENESeptember 2021April 2025Abandon4320NoNo
17598956COSMETIC COMPOSITIONSeptember 2021June 2025Allow4420YesNo
17442949Method of Making Prodrug for Sustained and Controlled ReleaseSeptember 2021November 2024Allow3710NoNo
17442746Doxorubicin Containing Nanoplexes and Uses ThereofSeptember 2021April 2025Allow4211NoNo
17439911NANOPARTICLE, METHOD FOR PRODUCING NANOPARTICLE, AND PHARMACEUTICAL COMPOSITIONSeptember 2021November 2024Abandon3810NoNo
17438892TRANSPARENT OR SEMITRANSPARENT INVERSE MICROLATICES OF POLYACRYLAMIDE AS OIL EMULSION DRIFT REDUCING AGENTSeptember 2021May 2025Allow4420NoNo
17401654CIPROFLOXACIN POLYMORPH AND ITS USEAugust 2021October 2024Abandon3810NoNo
17430497BIOBASED PEARLESCENT WAXESAugust 2021April 2025Allow4421NoNo
17400376Late-Stage Product Differentiation Process for Personal Care ProductsAugust 2021June 2024Allow3410YesNo
17310351PARTICLES OF A MIXTURE OF IRON(III)-OXYHYDROXIDE, SUCROSE AND ONE OR MORE STARCHES, PREFERABLY OF SUCROFERRIC OXYHYDROXIDEJuly 2021March 2025Allow4311NoNo
17423862Production and Use of Yeast Extract as a Medical AdjuvantJuly 2021April 2025Abandon4520NoNo
17251521POLYION COMPLEX MICELLE THAT INCLUDES ANTISENSE OLIGONUCLEOTIDE AND BLOCK COPOLYMER OF PEG BLOCK AND CATIONIC POLYMER, SAID BLOCK COPOLYMER HAVING NUMBER-AVERAGE MOLECULAR WEIGHT OF 3-10 kDaJuly 2021September 2024Abandon4510NoNo
17417160OIL-IN-WATER TYPE PEST REPELLENT COMPOSITIONJune 2021June 2024Abandon3610NoNo
17417263METHOD FOR CONTROLLING WEEDJune 2021August 2024Abandon3810NoNo
17415204Biofertilizing Bacterial StrainJune 2021February 2025Allow4410NoNo
17413104DEPOSITION SYSTEM FOR HAIRJune 2021March 2025Allow4520NoNo
17413361DEPOSITION SYSTEM FOR HAIRJune 2021December 2024Allow4221NoNo
17312579ANTIMICROBIAL IMPLANTABLE MEDICAL DEVICESJune 2021March 2025Abandon4620YesNo
17311528CANNABIS-BASED SELF-EMULSIFYING PRODUCTJune 2021July 2024Abandon3710NoNo
17311129HIGH-CONTENT AND SUSTAINED-RELEASE RETINOID CAPSULE, AND COMPOSITION FOR REDUCING WRINKLES, CONTAINING SAMEJune 2021April 2025Allow4630NoNo
17311010BIOCOMPATIBLE STRUCTURE COMPRISING HOLLOW CAGE, AND MANUFACTURING METHOD THEREFORJune 2021August 2024Abandon3810NoNo
17311145METHOD FOR FORMING COATING FILMJune 2021June 2025Allow4930YesNo
17296725COATING FILM FOR SKINMay 2021January 2025Abandon4420NoNo
17295284METHOD FOR TREATING HAIR, COMPRISING THE APPLICATION OF COATED PIGMENTS AND SILANESMay 2021June 2024Abandon3720NoNo
17316857METHOD FOR AUTOMATICALLY PRODUCING INDIVIDUALIZED TABLETS, AND TABLET PRESS FOR AUTOMATICALLY PRODUCING INDIVIDUALIZED TABLETSMay 2021January 2025Allow4421YesNo
17307605NANOPARTICLE FORMULATIONS OF IKE AND METHODS OF USE THEREOFMay 2021July 2024Abandon3801NoNo
17290773PH-SENSITIVE CARBON NANOPARTICLES, PREPARATION METHOD THEREFOR, AND DRUG DELIVERY USING SAMEMay 2021May 2025Allow4830NoNo
17290206COMPOSITION OF ACTIVE INGREDIENTS, FOR CARE AND SURFACE MODIFICATION OF HUMAN HAIRApril 2021October 2024Abandon4220NoNo
17288983OIL-IN-WATER-TYPE SKIN EXTERNAL AGENTApril 2021March 2025Abandon4630NoNo
17289117MEDICAL DEVICE AND METHOD FOR PRODUCING THE SAMEApril 2021July 2024Abandon3810NoNo
17288168COMPOSITION COMPRISING AT LEAST ONE SILICONE ACRYLIC COPOLYMER AND AT LEAST ONE CATIONIC ACRYLIC COPOLYMERApril 2021December 2024Abandon4410NoNo
17285623SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING AN IMMUNOMODULATING AGENT AND USES THEREOFApril 2021December 2024Allow4421NoNo
17284841Tunable Process for Silica Capsules/Spheres Preparation and Their UseApril 2021October 2024Allow4220NoNo
17283103COMPOSITION FOR TREATMENT OF VITREOUS DISEASE OR DISORDERApril 2021May 2025Allow5030YesNo
17207847Gelled Aerosol Product and Gel Forming KitMarch 2021January 2025Abandon4620YesNo
17274555METHOD OF MAKING ORAL DOSAGE FORMSMarch 2021June 2025Allow5120YesNo
17270747SUSTAINED-RELEASE OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES THEREOFFebruary 2021January 2025Abandon4621NoNo
17269972CANNABINOID BASED EMULSION SYSTEMS FOR INFUSED AQUEOUS COMPOSITIONSFebruary 2021July 2024Abandon4111NoNo
17269573SUNCARE FORMULATIONFebruary 2021October 2024Allow4440NoNo
17269574COLOR COSMETIC FORMULATIONFebruary 2021September 2024Allow4330NoNo
17258630COMPOSITION COMPRISING A SILICONE/POLYUREA OR SILICONE/POLYURETHANE COPOLYMER OR SILICONE/POLYUREA/POLYURETHANE COPOLYMER, A SILICONE RESIN, A VOLATILE ALKANE AND A C2-C8 MONOALCOHOLJanuary 2021April 2024Abandon3910NoNo
16971158RADIATION-TRIGGERED LIPOSOMESAugust 2020September 2024Allow4910NoNo
16480864MULTI-ARM BLOCK-COPOLYMERS FOR MULTIFUNCTIONAL SELF-ASSEMBLED SYSTEMSJuly 2019September 2024Allow6021NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LIPPERT, JOHN WILLIAM.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
1
(100.0%)
Filing Benefit Percentile
0.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner LIPPERT, JOHN WILLIAM - Prosecution Strategy Guide

Executive Summary

Examiner LIPPERT, JOHN WILLIAM works in Art Unit 1615 and has examined 72 patent applications in our dataset. With an allowance rate of 50.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner LIPPERT, JOHN WILLIAM's allowance rate of 50.0% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by LIPPERT, JOHN WILLIAM receive 1.57 office actions before reaching final disposition. This places the examiner in the 40% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LIPPERT, JOHN WILLIAM is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +44.3% benefit to allowance rate for applications examined by LIPPERT, JOHN WILLIAM. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 41.0% of applications are subsequently allowed. This success rate is in the 91% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 28.6% are granted (fully or in part). This grant rate is in the 19% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.